Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Cellular and Molecular Pathophysiology of Idiopathic Pulmonary Arterial Hypertension

특발성 폐동맥고혈압의 병태생리

  • Ra, Seung Won (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Sang-Do (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine)
  • 나승원 (울산대학교 의과대학 서울아산병원 호흡기내과) ;
  • 이상도 (울산대학교 의과대학 서울아산병원 호흡기내과)
  • Published : 2007.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension. In: Rubin L, Rich S, editors. Primary pulmonary hypertension. New York, NY: Marcel Dekker; 1997. p. 83-129
  2. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002;45:173-202 https://doi.org/10.1053/pcad.2002.130041
  3. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999;155:411-9 https://doi.org/10.1016/S0002-9440(10)65137-1
  4. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001;88:E2-11 https://doi.org/10.1161/01.RES.88.1.e2
  5. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-63 https://doi.org/10.1183/09031936.03.00038903
  6. Balabanian K, Foussat A, Dorfmuller P, Durand- Gasselin I, Capel F, Bouchet-Delbos L, et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:1419-25 https://doi.org/10.1164/rccm.2106007
  7. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001;22:451-8 https://doi.org/10.1016/S0272-5231(05)70283-5
  8. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5 https://doi.org/10.1056/NEJM199207093270202
  9. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159: 1925-32 https://doi.org/10.1164/ajrccm.159.6.9804054
  10. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21 https://doi.org/10.1056/NEJM199507273330403
  11. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9 https://doi.org/10.1161/01.CIR.0000099502.17776.C2
  12. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-46 https://doi.org/10.1172/JCI17500
  13. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9 https://doi.org/10.1056/NEJM199306173282402
  14. Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin LJ. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 1998;351:726-7 https://doi.org/10.1016/S0140-6736(05)78495-6
  15. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002;105:244-50 https://doi.org/10.1161/hc0202.101974
  16. Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996;94:2216-20 https://doi.org/10.1161/01.CIR.94.9.2216
  17. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-54 https://doi.org/10.1016/S0002-9343(99)80156-9
  18. Eddahibi S, Raffestin B, Pham I, Launay JM, Aegerter P, Sitbon M, et al. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol 1997;272:H1173-81
  19. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000;14:627-44
  20. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113: 685-700 https://doi.org/10.1016/S0092-8674(03)00432-X
  21. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-44 https://doi.org/10.1086/303059
  22. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-4 https://doi.org/10.1038/79226
  23. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000;37:741-5 https://doi.org/10.1136/jmg.37.10.741
  24. Chaouat A, Coulet F, Favre C, Simonneau G, Weitzenblum E, Soubrier F, et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004;59:446-8 https://doi.org/10.1136/thx.2003.11890
  25. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-34 https://doi.org/10.1056/NEJM200108023450503
  26. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene- Stewart L, Kasahara Y, et al. Expression of angiogenesis- related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001;195:367-74 https://doi.org/10.1002/path.953
  27. Rabinovitch M. Elastase and the pathobiology of unexplained pulmonary hypertension. Chest 1998;114: 213S-24S https://doi.org/10.1378/chest.114.3_Supplement.213S
  28. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000;6:698-702 https://doi.org/10.1038/76282
  29. Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 2000;105:21-34 https://doi.org/10.1172/JCI6539